CAS NO.: 148031-34-9
Assay: 98.5% min.
Gradus: Pharmaceutical Grade
Repono: Preserve in tight, light resistant containers, store in a refrigerator(2-8° C)
Formulae hypotheticae: C35H49N11O9S2
M. pondus: 831.96
Aspectus: Pulvis albus
Sequentia: Mpr-Harg-Gly-Asp-Trp-Pro-Cys)-NH2
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
1 . Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
2 .treat the adults and the children above6 years old chronic humanity flaw virus(HIV)infects. chronic humanity flaw virus(HIV)infects.
